Biomarker ID | 967 |
PMID | 22870138 |
Year | 2011 |
Biomarker | Osteopontin |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Plasma |
Subjects | Humans |
Regulation | Upregulated in PCa |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | PCa Vs BPH VS Healthy Donors |
Type of Biomarker | Diagnostic |
Cohort | PCa patients (29), benign prostate hyperplasia (BPH) (18) and control healthy donors (HD) (30) were selected for the study |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | ELISA |
Clinical | No |
Remarks | Antibodies against rOPN-GST were detected in 19/29 (66%), 6/18 (33%) and 3/30 (10%) plasma samples from PCa, BPH and HD, respectively |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |